Search arXiv⌕ Search
Home/Archive/arXiv

arXiv · 2112.10661

Trends in COVID-19 hospital outcomes in England before and after vaccine introduction, a cohort study

Peter Kirwan·Andre Charlett·Paul Birrell·Suzanne Elgohari·Russell Hope·Sema Mandal·Daniela De Angelis·Anne Presanis
View original source ↗Read source document ↗Export metadata ↓

Abstract

Widespread vaccination campaigns have changed the landscape for COVID-19, vastly altering symptoms and reducing morbidity and mortality. We estimate trends in mortality by month of admission and vaccination status among those hospitalised with COVID-19 in England between March 2020 to September 2021, controlling for demographic factors and hospital load. Among 259,727 hospitalised COVID-19 cases, 51,948 (20.0%) experienced mortality in hospital. Hospitalised fatality risk ranged from 40.3% (95% confidence interval 39.4-41.3%) in March 2020 to 8.1% (7.2-9.0%) in June 2021. Older individuals and those with multiple co-morbidities were more likely to die or else experienced longer stays prior to discharge. Compared to unvaccinated people, the hazard of hospitalised mortality was 0.71 (0.67-0.77) with a first vaccine dose, and 0.56 (0.52-0.61) with a second vaccine dose. Compared to hospital load at 0-20% of the busiest week, the hazard of hospitalised mortality during periods of peak load (90-100%), was 1.23 (1.12-1.34). The prognosis for people hospitalised with COVID-19 in England has varied substantially throughout the pandemic and according to case-mix, vaccination, and hospital load. Our estimates provide an indication for demands on hospital resources, and the relationship between hospital burden and outcomes.

Explore related subjects

stat.AP

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Peter Kirwan, Andre Charlett, Paul Birrell, Suzanne Elgohari, Russell Hope, Sema Mandal, Daniela De Angelis, Anne Presanis. 2022-08-03. Trends in COVID-19 hospital outcomes in England before and after vaccine introduction, a cohort study. https://doi.org/10.1038/s41467-022-32458-y

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

Online activity prediction via generalized Indian buffet process models

Online A/B tests are the standard tool for data-driven decision-making at scale. Among the design choices with the largest impact on statistical power is the triggering mechanism: how many users to expose and for how long. This often requires forecasting user engagement, i.e., whether enough users will trigger, and when a target participation level will be reached, from limited pilot data. We introduce a Bayesian nonparametric model for predicting both new-user counts and total triggers, accommodating the heavy-tailed engagement patterns typical of web experiments. All predictive quantities can be computed without intensive numerical procedures such as Markov chain Monte Carlo (MCMC) or variational inference. We evaluate on three public datasets (over 450 public benchmark evaluations) and a proprietary benchmark drawn from 759 production A/B tests comprising 1,774 arms. Across the benchmark analyses, our models are competitive and frequently improve accuracy in forecasting new users, total triggers, and time to reach a target sample size compared with state-of-the-art competitors, especially when only a few pilot days are observed.

stat.AP↗
arXiv2026

Spending Scarce Confirmatory PET Measurements: Target-Aligned Validation in A4/LEARN

Anti-amyloid therapies and blood-based biomarkers are changing Alzheimer disease workups into a two-stage measurement workflow: screen broadly with cheaper information, then spend scarce confirmatory amyloid measurements where they support the decision that will be reported. Amyloid positron-emission tomography (PET) remains one such protocol measurement for amyloid burden, but PET slots, trial budgets, and payer-facing evidence packages are finite. This paper asks a deliberately operational question: when is simple transparent PET validation enough, and when is a fitted residual-uncertainty score worth the added complexity? For a weighted protocol target, the first-order value of validating subject i is the product of target influence and residual protocol uncertainty. Generic uncertainty sampling uses only the second factor and can spend PET measurements on subjects that are hard to predict but weak for the scientific, clinical, or commercial claim. We apply this rule to the A4/LEARN PET archive, treating observed PET as a design laboratory for scarce-confirmation studies. For the primary APOE4 carrier versus non-carrier contrast in Centiloid 24-or-higher PET positivity, simple APOE4-balanced validation recovers nearly all of the target-specific gain: at PET budget 200, the confidence-interval width ratio relative to random validation is 0.923 for APOE4 balancing and 0.914 for target-specific scoring, while generic uncertainty sampling is 0.980. Other targets behave differently: target-specific scoring gives larger gains for an age-slope analysis and for cutoff-indexed PET positivity. The practical message is simple: spend scarce protocol measurements according to the claim being validated, not only according to prediction uncertainty.

stat.AP↗
arXiv2026

Identifying Damage Pathways Linking Sequence Composition to Storage Failure in DNA Data Storage via High-Dimensional Mediation Analysis

DNA data storage offers extraordinary information density and long-term durability, but its reliability is limited by sequence-dependent errors introduced during synthesis and accumulated during storage. It remains unclear how sequence composition is associated with storage failure through specific molecular damage components. We develop a high-dimensional semiparametric mediation framework for survival outcomes. GC content is treated as the exposure, a high-dimensional baseline damage spectrum (a vector of per-read damage counts stratified by trinucleotide context and error type) as the mediator, and storage-quality failure as the outcome. Nonlinear covariate effects in both the mediator and survival models are approximated using deep neural networks. A three-step procedure combining product-of-coefficients screening, Smoothly Clipped Absolute Deviation (SCAD) penalized estimation, and joint significance testing is developed for mediator selection and inference. Applied to an aging experiment on electrochemically synthesized DNA, the method identifies 14 significant mediators, all corresponding to single-base deletions, with estimated mediated effects concentrated in trinucleotide contexts ending in C. These results reveal deletion-type damage as a major pathway linking sequence composition to reduced archival reliability and suggest candidate sequence features for future optimization and error-control strategies. The proposed framework thus offers a mechanism-oriented statistical approach for understanding and improving the reliability of DNA data storage.

stat.AP↗